METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TREATMENT OF MODERATE PREECLAMPSIA Russian patent published in 2019 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to obstetrics and can be used for prediction of clinical effectiveness of preeclampsia of moderate severity in pregnant women in gestation period of 24–37 weeks, including in patients with chronic arterial hypertension. That is ensured by determining the relative CCR2+ cell count in the neutrophil population before the initiation of the therapy in the pregnant women at the gestation period of 24–37 weeks, and measuring the average arterial pressure. If the relative CCR2+ cell count is less than or equal to 38.8 % and the average arterial pressure is less than or equal to 110 mm Hg, a positive effect of treating moderate preeclampsia is predicted, including in females with CAG. If the relative content of CCR2+ cells is more than 38.8 % and the average arterial pressure is more than 110 mm Hg, the absence of therapeutic effect is predicted.

EFFECT: use of the given method enables predicting the effectiveness of the moderate-to-severe preeclampsia therapy, including in pregnant women with chronic arterial hypertension, which is necessary to apply a personified management approach in this category of patients, which will improve perinatal outcomes.

1 cl, 5 ex, 1 tbl